KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Current Assets for 13 consecutive years, with $560.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 11.75% to $560.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $560.6 million through Dec 2025, down 11.75% year-over-year, with the annual reading at $560.6 million for FY2025, 11.75% down from the prior year.
  • Current Assets for Q4 2025 was $560.6 million at Xenon Pharmaceuticals, up from $480.1 million in the prior quarter.
  • The five-year high for Current Assets was $794.8 million in Q2 2022, with the low at $256.3 million in Q3 2021.
  • Average Current Assets over 5 years is $552.3 million, with a median of $559.8 million recorded in 2021.
  • The sharpest move saw Current Assets soared 207.52% in 2021, then tumbled 31.48% in 2023.
  • Over 5 years, Current Assets stood at $559.0 million in 2021, then grew by 7.38% to $600.3 million in 2022, then rose by 7.44% to $645.0 million in 2023, then decreased by 1.5% to $635.3 million in 2024, then fell by 11.75% to $560.6 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $560.6 million, $480.1 million, and $500.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.